Compare Sony Group Corp (SONY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Zoetis Inc — how do they compare? Sony Group Corp trades at $23.54 (market cap $138.43B), while Zoetis Inc trades at $73.46 (market cap $31.14B). The key difference: Sony Group Corp is far larger — about 4.4× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| SONY | ZTS | |
|---|---|---|
Market Cap | $138.43B | $31.14B |
Sector | Technology | Health |
52-Week High | $30.26 | $156.76 |
52-Week Low | $19.32 | $71.91 |
Enterprise Value | $136.35B | $38.70B |
Dividend Yield | 0.67% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony's stock is trading at $23.48, down 1.43% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong cash flow of $1.07 trillion in 2025 and beat EPS estimates in two of the last three quarters, though Q1 2026 was a miss. Recent news highlights success from Spider-Man: Brand New Day and a joint venture with TSMC for image sensors, signaling growth in entertainment and technology segments.
The investment outlook is positive, driven by analyst consensus favoring a buy rating (68.75%) and potential upside from blockbuster films and sensor innovation. Key risks include a projected net loss in 2026, competitive pressures in gaming, and currency volatility. Fundamentals show solid revenue but margin compression, requiring careful monitoring of profit trends.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
